Hospital Professional News Ireland 2020 Oct ;77 (Page 36)
“In this study we investigated the capacity of monocytes to differentiate into dendritic cells in both Rheumatoid (RA) and Psoriatic arthritic patients (PsA). We observed different morphological and functional profiles between monocytes obtained from RA and PsA patients, with RA monocytes primed to differentiate into DC and exhibiting differentiation and activation markers at earlier time point compared to that of PsA. We further demonstrated a novel mechanism of action for Tofacitinib, a JAK/STAT inhibitor recently approved in the treatment of RA and PsA patients. We demonstrated that Tofacitinib inhibits Mo-DC differentiation in both RA and PsA patients, via the regulation of NOX5 expression and ROS production, giving us further insight into the use of the drug as a successful treatment strategy for IA.” -Dr. Viviana Marzaioli
Najm A, Masson FM, Preuss P, Georges S, Ory B, Quillard T, Sood S, Goodyear CS, Veale DJ, Fearon U, Le Goff B, Blanchard F.
Arthritis Rheumatol. 2020 Jul 19.
Canavan M, Marzaioli V, McGarry T, Bhargava V, Nagpal S, Veale DJ, Fearon U.
Clin Exp Immunol. 2020 Jun 17
Gallagher L, Cregan S, Biniecka M, Cunningham C, Veale DJ, Kane DJ, Fearon U, Mullan RH.
Arthritis Rheumatol. 2020 Jun
Wade SM, McGarry T, Wade SC, Fearon U, Veale DJ.
J Rheumatol. 2020 Mar 1
Petrasca A, Phelan JJ, Ansboro S, Veale DJ, Fearon U, Fletcher JM.
Rheumatology (Oxford). 2020 Feb 11
Veale DJ, Fearon U.
Nat Rev Rheumatol. 2020 Feb
Canavan M, Wade SM, Veale DJ, Fearon U.
Ann Rheum Dis. 2020 Jan 8
[Epub ahead of print]